| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2019 | The Epidemiology of Gastric Cancers in the Era of Helicobacter pylori Eradication: A nationwide cancer registry-based study in Taiwan | Chang J.S.; SUNG-HSIN KUO ; Chu P.-Y.; Shan Y.-S.; Tsai C.-R.; Tsai H.-J.; Chen L.-T. | Cancer Epidemiology Biomarkers and Prevention | 9 | 9 | |
| 2016 | Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer | Chiang N.-J.; CHIUN HSU ; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Huang S.-F.; Chen L.-T. | Scientific Reports | 16 | 14 | |
| 2011 | Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study | Ch'Ang H.-J.; Lin Y.-L.; HSIU-PO WANG ; Chiu Y.-F.; MING-CHU CHANG ; CHIH-HUNG HSU ; YU-WEN TIEN ; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG ; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. | International Journal of Radiation Oncology Biology Physics | 19 | 17 | |
| 2012 | Krüppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma | Chang V.H.S.; Chu P.-Y.; Peng S.-L.; TSUI-LIEN MAO ; Shan Y.-S.; Hsu C.-F.; Lin C.-Y.; Tsai K.K.C.; Yu W.C.Y.; Ch'Ang H.-J. | American Journal of Pathology | 28 | 25 | |
| 2021 | Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study | Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG ; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. | Therapeutic Advances in Medical Oncology | 2 | 4 | |
| 2015 | Loss of Egr-1 sensitizes pancreatic β-cells to palmitate-induced ER stress and apoptosis | Cheong M.-W.; Kuo L.-H.; Cheng Y.-N.; Tsai P.-J.; Ho L.-C.; Tai H.-C.; Chiu W.-T.; Chen S.-H.; Lu P.-J.; Shan Y.-S.; LEE-MING CHUANG ; Tsai Y.-S. | Journal of Molecular Medicine | 17 | 17 | |
| 2013 | Management of gastric cancer in Asia: Resource-stratified guidelines | Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH ; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. | The Lancet Oncology | 386 | 230 | |
| 2020 | A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study | Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG ; Hsiao H.-H.; Shen W.-C.; CHIUN HSU ; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | European Journal of Cancer | 7 | 7 | |
| 2020 | Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study | Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG ; CHIUN HSU ; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | Liver International | 5 | 5 | |
| 2020 | An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas | Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; CHIUN HSU ; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. | Oncologist | 4 | 4 | |
| 2021 | Survival outcomes of management in metastatic gastric adenocarcinoma patients | Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; CHUN-JU CHIANG ; Li A.F.-Y.; HSIU-PO WANG ; Wang T.-E.; Bai L.-Y.; MING-SHIANG WU ; Chen L.-T.; Liu T.-W.; Yang Y.-H. | Scientific Reports | 10 | 7 | |
